Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.
Professor Merrick Ross, M.D., of the MD Anderson Cancer Center in Houston, Texas, and a Principal Investigator for the Phase 2 study of PV-10 for metastatic melanoma, will deliver a presentation entitled "Intralesional therapy: local/regional control and implications for systemic response," at 3:15 p.m. EST. The congress will be held at the Marriott Waterside Hotel in Tampa, Florida from November 9 - 13.
Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds